Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Mariana Jeong

Physician Assistant Columbia, SC Physician Assistant

NPI 1295481356 CMS profile 11308932

2611 Forest Dr Ste 200, Columbia, SC 29204

Open in the dashboard

General payments

$3,726

218 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mariana Jeong of Columbia, SC is reported in the CMS Open Payments database as having received $3,726 across 218 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $156 8
2024 General $965 53
2023 General $1,525 93
2022 General $1,080 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mariana Jeong
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Mariana Jeong were reported at $156. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Mariana Jeong Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $1,080 $155 $48–$522 $149
2023 $1,525 $167 $52–$557 $160
2024 $965 $178 $55–$600 $164
2025 $156 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Novo Nordisk Inc $721 49 payments
  2. AstraZeneca Pharmaceuticals LP $476 28 payments
  3. Lilly USA, LLC $252 14 payments
  4. GlaxoSmithKline, LLC. $230 18 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $195 11 payments
  6. ITI, Inc. $186 9 payments
  7. Daiichi Sankyo Inc. $137 6 payments
  8. Pfizer Inc. $135 8 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $105 5 payments
  10. Merck Sharp & Dohme Corporation $105 6 payments
  11. Other $1,186 64 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $3,726 218 payments
Products named General payments · program years 2022–2025
  1. Ozempic $436 25 payments
  2. FARXIGA $337 19 payments
  3. RYBELSUS $335 24 payments
  4. TRELEGY ELLIPTA $230 18 payments
  5. Wegovy $200 16 payments
  6. Kerendia $195 11 payments
  7. CAPLYTA $186 9 payments
  8. MOUNJARO $171 10 payments
  9. INJECTAFER $137 6 payments
  10. PAXLOVID $118 7 payments
  11. Other $2,696 155 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 113 drugs

Part D claims

5,925

Median for Physician Assistant: 241

Drug cost

$569,523

Median for Physician Assistant: $4,110

Branded share of claims

20.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 43 $72,596
Jardiance Empagliflozin Brand 51 $66,069
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 76 $64,006
Farxiga Dapagliflozin Propanediol Brand 60 $61,906
Eliquis Apixaban Brand 46 $37,756
Trulicity Dulaglutide Brand 20 $34,921
Rybelsus Semaglutide Brand 11 $32,078
Januvia Sitagliptin Phosphate Brand 36 $28,803
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 29 $27,217
Mounjaro Tirzepatide Brand 18 $27,082

The 10 drugs with the highest cost, of 113 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$21,767

Of which drugs: $994

Medicare patients

109

Average age 71

Services billed

659

83 women, 26 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 40%
Arthritis 37%
Ischemic heart disease 20%
Chronic kidney disease 16%
Depression 16%
Atrial fibrillation 13%
COPD 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 12 12 $941

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $105
$105 60 —
Korlym
  • Corcept Therapeutics $69
$69 — —
YUPELRI
  • Mylan Specialty L.P. $62
$62 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $58
$58 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $37
  • Lilly USA, LLC $18
$55 51 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

218 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record